3.4. Connectivity Map Analysis and Drug Sensitivity Profiling Identify TG-101348 (Fedratinib) as a Potential Drug Reversing KRAS-Driven Pancreatic Ductal Adenocarcinoma Gene Signature. The gene discussed is KRAS; the disease is pancreatic ductal adenocarcinoma.